{"id":"nct:NCT06793397","kind":"trial","title":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","authors":["Cybin IRL Limited"],"author_count":1,"year":2025,"published":"2025-01-27","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT06793397","source_url":"https://clinicaltrials.gov/study/NCT06793397","archive_url":"https://space-kitty.com/papers/nct:NCT06793397","updated":"2026-10-27","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD. For more information about the EMBRACE study, including participating study locations, and to register your interest in learning more about participation, please visit the study website: https://embrace-mdd-trial.com/","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"peer_reviewed":null,"categories":["Major Depressive Disorder (MDD)","Depression in Adults","Depression - Major Depressive Disorder","Depression Disorders","Depression Disorder","Depression"],"details":{"acronym":"EMBRACE","status":"RECRUITING","phase":"PHASE3","study_type":"INTERVENTIONAL","enrollment":330,"sponsor":"Cybin IRL Limited","conditions":["Major Depressive Disorder (MDD)","Depression in Adults","Depression - Major Depressive Disorder","Depression Disorders","Depression Disorder","Depression"],"interventions":["DRUG: CYB003","BEHAVIORAL: Psychological Support"],"start_date":"2025-12-10","start_date_type":"ACTUAL","primary_completion_date":"2027-06-07","has_results":false,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"psychiatric-therapeutics","name":"Novel Psychiatric Therapeutics","domain_slug":"neuroscience"}],"cited_in_dossiers":[]}